Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans
Published: 07:15 19 Nov 2026 EST
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and preparations for a Phase 3 trial.
L’Huillier explained how the Regenerative Medicine Advanced Therapy designation will enable closer engagement with the FDA on clinical development, manufacturing and potential accelerated approval pathways.
He highlighted updated results showing 87% overall survival and 71% progression-free survival among patients receiving the second-generation iSCIB1+ treatment, now known as inzi. More than one-third achieved complete responses, with L’Huillier pointing to the durability of results.
The interview also explores progress with Modi-1, where almost 50% of patients in the renal cancer cohort demonstrated strong vaccine-related immune responses.
L’Huillier provided updates on Scancell's ImmunoBody and GlyMab platforms, including developments involving Genmab, before discussing the proposed reverse merger with Neuphoria and associated funding.
The transaction remains targeted for completion by the end of 2026 or early 2027, supporting plans to advance inzi into Phase 3 development.
For more interviews and updates from listed companies, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications for future content.
Read Proactive’s Editorial Policy here.
#Scancell #ScancellHoldings #Melanoma #CancerImmunotherapy #Biotech #FDA #RMAT #ClinicalTrials #Phase3Trial #Oncology #CancerResearch #Immunotherapy #BiotechStocks #HealthcareInvesting #Modi1 #Neuphoria #Nasdaq #ProactiveInvestors